Seagen’s Acquisition By Pfizer For $43 Billion Is Complete

At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.

Explore Firm Details

The Life Sciences and Public M&A teams advised Guggenheim Securities as financial advisor to Pfizer Inc.(NYSE: PFE) in the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN).

United States

The Life Sciences and Public M&A teams advised Guggenheim Securities as financial advisor to Pfizer Inc.(NYSE: PFE) in the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN). Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.

Guggenheim Securities is the investment banking and capital markets business of Guggenheim Partners.

The Goodwin team was led by Stuart Cable, James Matarese, Blake Liggio and Caitlin Tompkins.

For additional details on the acquisition, please read the press release.

Contributor

Explore Firm Details

See More Popular Content From